Pure Global
NCT06383598

PD-L1 Specific [68Ga]-Nb-1 Nanobody Probe for PET Imaging in Solid Tumors

Peking University Cancer Hospital & Institute·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Solid Tumor
Drug/Device/Intervention
18F-FDG
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Peking University Cancer Hospital & Institute
Location
Beijing, China
Timeline & enrollment
Phase
N/A
Start date
May 09, 2024
End date
Dec 01, 2026
Enrollment
50 participants
Primary outcome

Standardized uptake value（SUV）

Summary

The objective of the study is to constrcut a noninvasive approach 68Ga-Nb-1 PET/CT to detect
 the PD-L1 expression of tumor lesions in patients with solid tumors and to identify patients
 benefiting from anti-PD-L1 treatment.

ICD-10 classifications
Malignant neoplasm: Connective and soft tissue, unspecifiedCarcinoma in situ, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm of other connective and soft tissueMalignant neoplasm: Lip, unspecified, inner aspect
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06383598
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06383598 through Pure Global AI's free database. This phase not specified trial is sponsored by Peking University Cancer Hospital & Institute and is currently Recruiting. The study focuses on Solid Tumor. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.